In Reply We thank Qi and colleagues for their careful review of our article and their thoughtful comments. We agree that the progression-free survival (PFS) of the osimertinib and bevacizumab combination seen in our study1 is comparable to the median PFS with osimertinib alone in the FLAURA study.2 In our article, we note that there was a larger proportion of patients with preexisting brain metastases compared with the FLAURA population (31% vs 19%), and 16% of patients withdrew consent without progression and unrelated to toxic effects to pursue consolidative local therapy (n = 4) or continue with commercial osimertinib (n = 4). These factors may have influenced the PFS in our study.
Schoenfeld AJ, Yu HA. Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers—Reply. JAMA Oncol. 2020;6(12):1983. doi:10.1001/jamaoncol.2020.4824
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.